128 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
30 May 24
Entry into a Material Definitive Agreement
4:09pm
in various solid tumors. Uza-cel is engineered to express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Data indicate
8-K
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
directed to up to five collaboration targets and (ii) personalized therapies utilizing αβ T-cell receptors (TCRs) isolated from a patient
8-K
EX-10.1
e6n 1z9l0elwtxiiia
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-99.1
kgaru
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.2
uo1gi46cy9yb ggbvm
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
fg2x1
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-99.1
ptv 7mli8
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
by0fp4pe71e t3x
30 May 23
Business combination disclosure
4:21pm
8-K
rh9g9iul71
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
4mr6p24p5p2xq ao2ex
22 May 23
Business combination disclosure
7:01am
8-K
7nbry x5pch
22 May 23
Other Events
6:59am
8-K
EX-99.1
00k11znotag 67
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
ihxjutuj3e
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
iya 80dc2z5
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm